Moderna's mRESVIA RSV Vaccine Approved by Health Canada for Adults 60 and Older

Nov 8, 2024, 03:13 PM

Moderna has received approval from Health Canada for its respiratory syncytial virus (RSV) vaccine, mRESVIA, for adults aged 60 years and older. This marks the first mRNA-based vaccine for RSV to be authorized in Canada. The approval was announced on Friday, making it a significant milestone for the vaccine maker. The stock ticker for Moderna is $MRNA.